Pharmacotherapy for cataplexy

Sleep Medicine Reviews

Volumn 8, Issue 5, 2004, Pages 355-366

  Houghton, William C ^a   Scammell, Thomas E ^b   Thorpy, Michael ^c  

^a JAZZ PHARMACEUTICALS   (United States)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Anticataplectics; Cataplexy; Narcolepsy; Pharmacotherapy; Review

Indexed keywords

AMITRIPTYLINE; AMPHETAMINE; BOFAROMINE; CENTRAL DEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; FEMOXETINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; METHYLPHENIDATE; MODAFINIL; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; OXYBATE SODIUM; PAROXETINE; PHENELZINE; PLACEBO; PROTRIPTYLINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; ZIMELDINE;

ADRENERGIC STIMULATION; AGITATION; ANOREXIA; ANORGASMIA; ANTICHOLINERGIC EFFECT; ANXIETY; BLOOD DYSCRASIA; CATAPLEXY; CHOLINERGIC NERVE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG ABUSE; DRUG CONTRAINDICATION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DYSTOCIA; EDEMA; EJACULATION DISORDER; EMOTION; FATIGUE; GASTROINTESTINAL SYMPTOM; GROWTH HORMONE RELEASE; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEPATITIS; HOFFMANN REFLEX; HUMAN; HYPERREFLEXIA; HYPERTENSIVE CRISIS; HYPERTHERMIA; HYPOTENSION; IMPOTENCE; INFECTION; INSOMNIA; IRRITABILITY; LEUKOPENIA; LIBIDO DISORDER; MOTONEURON; MOTOR DYSFUNCTION; MUSCLE TWITCH; MYOCLONUS; NARCOLEPSY; NAUSEA; NERVOUSNESS; NEUROBIOLOGY; NEUROLEPTIC MALIGNANT SYNDROME; ORGASM DISORDER; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PERIPHERAL EDEMA; REM SLEEP; RESTLESSNESS; REVIEW; RIGIDITY; SEDATION; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT; SLEEP APNEA SYNDROME; SLEEP DISORDER; SOMNOLENCE; SWEATING; TACHYCARDIA; TREATMENT OUTCOME; TREMOR; URINE INCONTINENCE; URINE RETENTION; VASCULAR HEADACHE; VOMITING; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 4444333999     PISSN: 10870792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smrv.2004.01.004     Document Type: Article

References (90)

1. Shiromani P.J., Armstrong D.M., Bruce G., Hersh L.B., Groves P.M., Gillin J.C. Relation of pontine choline acetyltransferase immunoreactive neurons with cells which increase discharge during REM sleep. Brain Res Bull. 18:1987;447-455
2. Maloney K.J., Mainville L., Jones B.E. Differential c-Fos expression in cholinergic, monoaminergic, and GABAergic cell groups of the pontomesencephalic tegmentum after paradoxical sleep deprivation and recovery. J Neurosci. 19:1999;3057-3072
3. Nitz D., Siegel J. GABA release in the dorsal raphe nucleus: role in the control of REM sleep. Am J Physiol. 273:(1 Pt 2):1997;R451-R455
4. Gervasoni D., Darracq L., Fort P., Souliere F., Chouvet G., Luppi P.H. Electrophysiological evidence that noradrenergic neurons of the rat locus coeruleus are tonically inhibited by GABA during sleep. Eur J Neurosci. 10:1998;964-970
5. Curtis D.R., Hosli L., Johnston G.A., Johnston I.H. The hyperpolarization of spinal motoneurones by glycine and related amino acids. Exp Brain Res. 5:1968;235-258
6. Morales F.R., Engelhardt J.K., Soja P.J., Pereda A.E., Chase M.H. Motoneuron properties during motor inhibition produced by microinjection of carbachol into the pontine reticular formation of the decerebrate cat. J Neurophysiol. 57:1987;1118-1129
7. Mileykovskiy B.Y., Kiyashchenko L.I., Siegel J.M. Cessation of activity in red nucleus neurons during stimulation of the medial medulla in decerebrate rats. J Physiol. 545:(Pt 3):2002;997-1006
8. Wu M.F., John J., Boehmer L.N., Yao D., Nguyen G.B., Siegel J.M. Activity of dorsal raphe cells across the sleep-waking cycle and during cataplexy in narcoleptic dogs. J Physiol. 2003
9. Simon-Arceo K., Ramirez-Salado I., Calvo J.M. Long-lasting enhancement of rapid eye movement sleep and pontogeniculooccipital waves by vasoactive intestinal peptide microinjection into the amygdala temporal lobe. Sleep. 26:2003;259-264
10. Gulyani S., Wu M.F., Nienhuis R., John J., Siegel J.M. Cataplexy-related neurons in the amygdala of the narcoleptic dog. Neuroscience. 112:2002;355-365
11. Overeem S., Lammers G.J., van Dijk J.G. Weak with laughter. Lancet. 354:1999;838
12. Mignot E., Lammers G.J., Ripley B., Okun M., Nevsimalova S., Overeem S., et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 59:2002;1553-1562
13. Horvath T.L., Peyron C., Diano S., Ivanov A., Aston-Jones G., Kilduff T.S., et al. Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. J Comp Neurol. 415:1999;145-159
14. Hagan J.J., Leslie R.A., Patel S., Evans M.L., Wattam T.A., Holmes S., et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci USA. 96:1999;10911-10916
15. Peever J.H., Lai Y.Y., Siegel J.M. Excitatory effects of hypocretin-1 (orexin-A) in the trigeminal motor nucleus are reversed by NMDA antagonism. J Neurophysiol. 89:2003;2591-2600
16. Nishino S., Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol. 52:1997;27-78
17. Guilleminault C., Mignot E., Aldrich M., Quera-Salva M.A., Tiberge M., Partinen M. Prazosin contraindicated in patients with narcolepsy. Lancet. 2:1988;511
18. Aldrich M.S., Rogers A.E. Exacerbation of human cataplexy by prazosin. Sleep. 12:1989;254-256
19. Baldessarini R.J. Drugs and the treatment of psychiatric disorders. Depression and anxiety disorders. Hardman J.G., Limbirb L.E. The pharmacological basis of therapeutics. 10th ed:2001;447-459 McGraw-Hill, New York
20. Akimoto H., Honda Y., Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Syst. 21:1960;704-706
21. Hishikawa Y., Ida H., Nakai K., Kaneko Z. Treatment of narcolepsy with imipramine (Tofranil) and desmethylimipramine (Pertofran). J Neurol Sci. 3:1966;453-461
22. Gross M.D. A note on cataplexy treated with protriptyline. Dis Nerv Syst. 30:1969;418
23. Schmidt H.S., Clark R.W., Hyman P.R. Protriptyline: an effective agent in the treatment of the narcolepsy-cataplexy syndrome and hypersomnia. Am J Psychiatry. 134:1977;183-185
24. Bourdillon J.L. Treatment of narcolepsy. Br Med J. 1:1971;670
25. Guilleminault C., Carskadon M., Dement W.C. On the treatment of rapid eye movement narcolepsy. Arch Neurol. 30:1974;90-93
26. Linnoila M., Simpson D., Skinner T. Characteristics of therapeutic response to imipramine in cataplectic men. Am J Psychiatry. 137:1980;237-238
27. Guilleminault C., Wilson R.A., Dement W.C. A study on cataplexy. Arch Neurol. 31:1974;255-261
28. Chen C.N. The use of clomipramine as an REM sleep suppressant in narcolepsy. Postgrad Med J. 56:(Suppl 1):1980;86-89
29. Shapiro W.R. Treatment of cataplexy with clomipramine. Arch Neurol. 32:1975;653-656
30. Guilleminault C., Raynal D., Takahashi S., Carskadon M., Dement W. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand. 54:1976;71-87
31. Bental E., Lavie P., Sharf B. Severe hypermotility during sleep in treatment of cataplexy with clomipramine. Isr J Med Sci. 15:1979;607-609
32. Parkes J.D., Schachter M. Clomipramine and clonazepam in cataplexy. Lancet. 2:1979;1085-1086
33. Chen S.Y., Clift S.J., Dahlitz M.J., Dunn G., Parkes J.D. Treatment in the narcoleptic syndrome: self assessment of the action of dexamphetamine and clomipramine. J Sleep Res. 4:1995;113-118
34. USP Dispensing Information, Greenwood Village, CO:MICROMEDEX; 2002.
35. Chen C.-N. Sleep, depression and antidepressants. Br J Psychiatry. 135:1979;385-402
36. Martinez-Rodriguez J., Iranzo A., Santamaria J., Genis D., Molins A., Silva Y., Melendez R. Status cataplecticus induced by abrupt withdrawal of clomipramine. Neurologia. 17:2002;113-116
37. Grözinger M., Härtter S., Hiemke C., Griese E.U., Röschke J. Interaction of modafinil and clomipramine as comedication in a narcolepstic patient. Clin Neuropharmcol. 21:1998;127-129
38. McDaniel K.D. Clinical pharmacology of monoamine oxidase inhibitors. Clin Neuropharmacol. 9:1986;207-234
39. Wyatt R.J., Fram D.H., Buchbinder R., Snyder F. Treatment of intractable narcolepsy with a monoamine oxidase inhibitor. N Engl J Med. 285:1971;987-991
40. Roselaar S.E., Langdon N., Lock C.B., Jenner P., Parkes J.D. Selegiline in narcolepsy. Sleep. 10:1987;491-495
41. Hublin C., Partinen M., Heinonen E.H., Puukka P., Salmi T. Selegiline in the treatment of narcolepsy. Neurology. 44:1994;2095-2101
42. Mayer G., Meier-Ewert K., Hephata K. Selegeline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol. 18:1995;306-319
43. Gernaat H.B., Haffmans P.M., Knegtering H., Birkenhager T.K. Tranylcypromine in narcolepsy. Pharmacopsychiatry. 28:1995;98-100
44. Hohagen F., Mayer G., Menche A., Riemann D., Volk S., Meier-Ewert K.H., et al. Treatment of narcolepsy-cataplexy syndrome with the new selective and reversible MAO-A inhibitor brofaromine - a pilot study. J Sleep Res. 2:1993;250-256
45. McEvoy G.K. American Hospital Formulary Service Drug Information 2003. 2003;American Society of Health-System Pharmacists, Bethesda
46. Mendelsohn M.J. Monoamine oxidase inhibitors. Ford D.A., Delaney K.A., Ling L.J., Erickson T. Clinical toxicology. 2001;546-557 WB Saunders, Philadelphia, PA
47. Wing Y.K., Lee S., Chiu H.F., Ho C.K., Chen C.N. A patient with coexisting narcolepsy and morbid jealousy showing favourable response to fluoxetine. Postgrad Med J. 70:1994;34-36
48. Schachter M., Parkes J.D. Fluvoxamine and clomipramine in the treatment of cataplexy. J Neurol Neurosurg Psychiatry. 43:1980;171-174
49. Godbout R., Montplaisir J. The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness of narcoleptic patients. Clin Neuropharmacol. 9:1986;46-51
50. Schrader H., Kayed K., Bendixen Markset A.C., Treidene H.E. The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo. Acta Neurol Scand. 74:1986;297-303
51. Sandyk R. Efficacy of trazodone in narcolepsy. Eur Neurol. 24:1985;335-337
52. Frey J., Darbonne C. Fluoxetine suppresses human cataplexy: a pilot study. Neurology. 44:1994;707-709
53. Langdon N., Shindler J., Parkes J.D., Bandak S. Fluoxetine in the treatment of cataplexy. Sleep. 9:1986;371-373
54. Thirumalai S.S., Shubin R.A. The use of citalopram in resistant cataplexy. Sleep Med. 1:2000;313-316
55. Smith M., Parkes J.D., Dahlitz M. Venlafaxine in the treatment of the narcoleptic syndrome. J Sleep Res. 5:(Suppl 1):1996;217
56. Guilleminault C., Mancuso J., Salva M.A., Hayes B., Mitler M., Poirier G., Montplaisir J. Viloxazine hydrochloride in narcolepsy: a preliminary report. Sleep. 9:(1 Pt 2):1986;275-279
57. Larrosa O., de la Llave Y., Bario S., Granizo J.J., Garcia-Borreguero D. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep. 24:2001;282-285
58. Kratochvil C.J., Vaughan B.S., Harrington M.J., Burke W.J. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother. 4:2003;1165-1174
59. Krahn L.E., Moore W.R., Altschuler S.I. Narcolepsy and obesity: remission of severe cataplexy with sibutramine. Sleep Med. 2:2001;63-65
60. Tunnicliff G. Significance of γ-hydroxybutyric acid in the brain. Gen Pharmacol. 23:1992;1027-1034
61. Maitre M. The γ-hydroxybutyrate signaling system in brain: organization and functional implications. Prog Neurobiol. 51:1997;337-361
62. Mamelak M., Escriu J.M., Stokan O. The effects of gamma-hydroxybutyrate on sleep. Biol Psychiatry. 12:1977;273-288
63. Broughton R., Mamelak M. Effects of nocturnal gamma-hydroxybutyrate on sleep/wake patterns in narcolepsy-cataplexy. Can J Neurol Sci. 7:1980;23-31
64. Scharf M., Brown D., Woods M., Brown L., Hirschowitz J. The effects and effectiveness of γ-hydroxybutyrate in patients with narcolepsy. J Clin Psychiatry. 46:1985;222-225
65. Scrima L., Hartman P.G., Johnson F.H. Jr., Hiller F.C. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double blind subjective measures. Biol Psychiatry. 26:1989;331-343
66. Lammers G.J., Arends J., Declerck A.C., Ferrari M.D., Schouwink G., Troost J. Gamma-hydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep. 6:1993;216-220
67. Scrima L., Hartman P.G., Johnson F.H., Thomas E.E., Hiller F.C. The effects of γ-hydroxybutyrate on the sleep of narcolepsy patients: a double blind study. Sleep. 13:1990;479-490
68. ® Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 25:2002;42-49
69. ® Multicenter Study Group. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J Toxicol Clin Toxicol. 41:2003;131-135
70. ® Multicenter Study Group. A 12-month, open-label, multi-center extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep. 26:2003;31-35
71. ® (sodium oxybate) oral solution. Orphan Medical, Inc.
72. Black J.E., Ristanovic R., Mamelak M., Montplaisir J. Effect of increasing doses of sodium oxybate on nocturnal oxygen saturation: preliminary findings. Sleep. 25:(Suppl):2002;A474
73. Ristanovic R., Black J., Mamelak M., Montplaisir J. Analysis of dose effects of sodium oxybate on noctural respiratory disturbances. Sleep. 25:(Suppl):2002;A473
74. Gibson K.M., Hoffman G.F., Hodson A.K., Bottiglieri T., Jakobs C. 4-Hydroxybutyric acid and the clinical phenotype of succinic semialdehyde dehydrogenase deficiency, an inborn of GABA metabolism. Neuropediatrics. 29:1998;14-22
75. Van Cauter E., Plat L., Scharf M.B., Leproult R., Cespredes S., L'Hermite-Baleriaux M. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by γ-hydroxybutyrate in normal young men. J Clin Invest. 100:1997;745-753
76. Ristanovic R. decreased body-mass index (BMI) in narcolepstic patients treated with sodium oxybate. Sleep. 26:(Suppl):2003;A87
77. Kales A., Cadieux R., Soldatos C.R., Tan T.L. Successful treatment of narcolepsy with propranolol: a case report. Arch Neurol. 36:1979;650-651
78. Kales A., Soldatos C.R., Cadieux R., Bixler E.O., Tan T.L., Scharf M.B. Propranolol in the treatment of narcolepsy. Ann Intern Med. 91:1979;741-743
79. Meier-Ewert K., Matsubayashi K., Benter L. Propranolol: long-term treatment in narcolepsy-cataplexy. Sleep. 8:1985;95-104
80. Paulus W., Homberg V., Noth J. Cataplexy relieved by tiapride. Arch Neurol. 40:1983;828
81. Benbadis S.R. Effective treatment of narcolepsy with codeine in a patient receiving hemodialysis. Pharmacotherapy. 16:1996;463-465
82. Vaughn B.V., D'Cruz O.F. Carbamazepine as a treatment for cataplexy. Sleep. 19:1996;101-103
83. Guilleminault C., Aftab F.A., Karadeniz D., Philip P., Leger D. Problems associated with switch to modafinil - a novel alerting agent in narcolepsy. Eur J Neurol. 7:2000;381-384
84. Parkes J.D., Schachter M. Mazindol in the treatment of narcolepsy. Acta Neurol Scand. 60:1979;250-254
85. Iijima S., Sugita Y., Teshima Y., Hishikawa Y. Therapeutic effects of mazindol on narcolepsy. Sleep. 9:(1 Pt 2):1986;265-268
86. Bastuji H., Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry. 12:1988;695-700
87. Daniels E., King M.A., Smith I.E., Shneerson J.M. Health-related quality of life in narcolepsy. J Sleep Res. 10:2001;75-81
88. Littner M., Johnson S.F., McCall W.V., Anderson W.M., Davila D., et al. Standards of Practice Committee. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep. 24:2001;451-466
89. Thorpy M. Current concepts in the etiology, diagnosis and treatment of narcolepsy. Sleep Med. 2:2001;5-17
90. ® Risk Management Program. Drug Safety. 2004;. in press